Syngene is paying $36.5 million to acquire Emergent's shuttered biologics facility in the Bayview neighborhood of Baltimore, the Indian drugmaker said (PDF) Monday.

Bangalore, March 10, 2025: Syngene International Limited (‘Syngene’), a global contract research, development, and manufacturing organization (CRDMO), today announced the acquisition of its first ...

Syngene International a global contract research, development, and manufacturing organization (CRDMO), announced the acquisition of its first biologics site in the USA, fitted with multiple monoclonal ...

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance ...